Tryptamine Therapeutics Financial Overview
Tryptamine Therapeutics's market cap is currently AU$53.11M. The company's EPS TTM is AU$-0.007; its P/E ratio is ―; Tryptamine Therapeutics is scheduled to report earnings on February 20, 2025, and the estimated EPS forecast is AU$―. See an overview of income statement, balance sheet, and cash flow financials.